Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $1.8 million.

  • Vistagen Therapeutics' Non-Current Assets fell 2345.73% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.3 million, marking a year-over-year decrease of 2193.31%. This contributed to the annual value of $2.3 million for FY2025, which is 2401.88% down from last year.
  • According to the latest figures from Q4 2025, Vistagen Therapeutics' Non-Current Assets is $1.8 million, which was down 2345.73% from $2.0 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Non-Current Assets peaked at $4.2 million during Q1 2021, and registered a low of $1.8 million during Q4 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $3.3 million (2023), whereas its average is $3.1 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 234.2% in 2021, then crashed by 2401.88% in 2025.
  • Vistagen Therapeutics' Non-Current Assets (Quarter) stood at $3.8 million in 2021, then dropped by 3.04% to $3.7 million in 2022, then fell by 19.1% to $3.0 million in 2023, then decreased by 19.91% to $2.4 million in 2024, then decreased by 23.46% to $1.8 million in 2025.
  • Its Non-Current Assets stands at $1.8 million for Q4 2025, versus $2.0 million for Q3 2025 and $2.2 million for Q2 2025.